Adicet Bio develops allogeneic gamma delta CAR T cell therapies to target and eliminate cancer cells, utilizing the unique properties of gamma delta T cells for enhanced tissue homing and drug exposure. This approach addresses the need for effective, on-demand immunotherapies in the treatment of cancer and autoimmune diseases.
Funding
$98M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer immunotherapies face challenges in effectively targeting and eliminating cancer cells, particularly in solid tumors, while also requiring personalized approaches that are difficult to scale and deliver on-demand. Existing treatments may lack sufficient tissue homing capabilities and drug exposure at the tumor site, limiting their efficacy.
Solution
Adicet Bio develops allogeneic gamma delta CAR T-cell therapies designed to enhance the body's ability to fight cancer. These therapies leverage the unique properties of gamma delta T cells, a subset of immune cells known for their innate ability to recognize and kill cancer cells, as well as their capacity to infiltrate tissues. By engineering these cells with chimeric antigen receptors (CARs), Adicet aims to create off-the-shelf immunotherapies that can be readily deployed to target specific cancer antigens, improve tissue homing, and increase drug exposure at the tumor site, offering a potentially more effective and accessible treatment option.
Target Audience
The primary target audience includes patients with cancer and autoimmune diseases who may benefit from novel immunotherapies, as well as oncologists and hematologists seeking more effective and accessible treatment options.
Features
- Allogeneic approach enables "off-the-shelf" availability, reducing the need for patient-specific manufacturing.
- Gamma delta T cells offer enhanced tissue homing capabilities, potentially improving penetration into solid tumors.
- CAR engineering allows for targeted recognition and elimination of cancer cells expressing specific antigens.
- Designed for improved drug exposure at the tumor site, maximizing therapeutic effect.